Results 61 to 70 of about 1,457,629 (200)
Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling [PDF]
The "metabolic cocktail" comprising glucose-insulin-potassium administrated at reperfusion reduces infarct size in the in vivo rat heart. We propose that insulin is the major component mediating this protection and acts via Akt prosurvival signaling ...
Sack, M.N. +3 more
core
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima +20 more
wiley +1 more source
A role for Syk-kinase in the control of the binding cycle of the β2 integrins (CD11/CD18) in human polymorphonuclear neutrophils [PDF]
A fine control of β2 integrin (CD11/CD18)-mediated firm adhesion of human neutrophils to the endothelial cell monolayer is required to allow ordered emigration.
Walzog, Barbara +9 more
core +1 more source
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart +15 more
wiley +1 more source
The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton\u27s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma.
Bhatia, Sumeet +35 more
core +2 more sources
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
McCaig, Alison M. +14 more
core +1 more source
Bruton tyrosine kinase inhibitors and cardiovascular adverse events
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli +4 more
wiley +1 more source
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley +1 more source
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao +8 more
wiley +1 more source

